

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Megestrol acetate

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
<p>megestrol acetate suspension (Megace Suspension and Megace ES Suspension)</p> <p>megestrol acetate tablets (Megace tablets)</p>

APPROVAL CRITERIA

Requests for megestrol acetate suspension (Megace Suspension and Megace ES Suspension) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Cachexia, or an unexplained significant weight loss in individuals with HIV/AIDS; **OR**
 - B. Endometriosis (AHFS); **OR**
 - C. Ovarian cancer, including epithelial, fallopian tube, and primary peritoneal cancers (NCCN 2A); **OR**
 - D. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS); **OR**
 - E. Prostatic hypertrophy (AHFS); **OR**
 - F. Endometrial hyperplasia (AHFS); **OR**
 - G. Ovulation control in the prevention of conception (AHFS).

Requests for megestrol acetate tablets (Megace tablets) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Advanced, inoperable, recurrent Breast cancer; **AND**
 - B. Individual is using for palliative management;

OR

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

C. Endometrial/uterine cancer; **AND**

D. Individual is using for palliative management;

OR

E. Endometriosis (AHFS);

OR

F. Ovarian cancer, including epithelial, fallopian tube, and primary peritoneal cancers (NCCN 2A);

OR

G. Cachexia and/or anorexia in individuals with cancer/neoplastic disease (DrugPoints B IIa, AHFS);

OR

H. Prostatic hypertrophy (AHFS);

OR

I. Endometrial hyperplasia (AHFS);

OR

J. Ovulation control in the prevention of conception (AHFS).

Notes:

- I. The use of megestrol acetate tablets in other types of neoplastic disease is not recommended, however, AHFS, DrugPoints, and Clinical Pharmacology all have listed cachexia/anorexia as an off-label indication for megestrol acetate without stating a specific dosage form.
- II. Oral suspensions containing 200 mg/5 mL are *not* bioequivalent or interchangeable on a mg-per-mg basis with the oral suspension containing 625 mg/5 mL (Megace ES).

State Specific Mandates		
State name N/A	Date effective N/A	Mandate details (including specific bill if applicable) N/A

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/daily_med/about.cfm. Accessed: 4/2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.